article thumbnail

The role of biosimilars in reducing out-of-pocket costs for patients

Drug Patent Watch

Breaking Down Barriers to Affordable Healthcare: The Power of Biosimilars As we navigate the complex landscape of modern healthcare, one thing is clear: the cost of prescription medications is a significant burden for many patients. So, how do biosimilars work? But the benefits of biosimilars extend far beyond individual patients.

article thumbnail

The impact of biosimilars on biologic drug life cycle management

Drug Patent Watch

The Biosimilar Revolution: How It's Changing the Game for Biologic Drug Manufacturers As the pharmaceutical industry continues to evolve, one trend is gaining significant attention: the rise of biosimilars. In this article, we'll explore the impact of biosimilars on biologic drug life cycle management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

In this article, Stephan Schann, Chief Scientific Officer at Domain Therapeutics , explains why this class of drug target is so useful despite the challenges they present. G protein-coupled receptors (GPCRs) are a highly validated drug target family – accounting for 30-35 percent of all approved drugs.

Disease 59
article thumbnail

Handling Drug Patent Invalidity Claims

Drug Patent Watch

However, with the increasing competition from generic and biosimilar manufacturers, patent invalidity claims have become a significant challenge for pharmaceutical companies. In this article, we will delve into the strategies and considerations for handling drug patent… Source

article thumbnail

Addressing supply chain challenges for biosimilar products

Drug Patent Watch

Navigating the Complex World of Biosimilar Supply Chains As the demand for biosimilars continues to grow, so do the challenges associated with their supply chains. One of the biggest hurdles biosimilar manufacturers face is the need to replicate complex biological processes with precision and consistency.

article thumbnail

Building the requisite clinical development infrastructure for medical innovation to thrive

Drug Target Review

Vishal has played a critical role in the creation of transformative patient treatments, including blockbuster CAR T-cell therapies, immunotherapies and biosimilars, showcasing his commitment to improving patient lives.

article thumbnail

Drug Patent Expirations: Unlocking Strategic Investment Opportunities

Drug Patent Watch

When a patent expires, the original manufacturer's market share is often disrupted, allowing generic or biosimilar versions of the medication to enter the market. This has led to a significant increase in investment in the generic and biosimilar sectors. Read the full article here: [link]